Barclays PLC Increases Position in Cardiff Oncology, Inc. (NASDAQ:CRDF)

Barclays PLC increased its stake in shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) by 291.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 53,089 shares of the company’s stock after purchasing an additional 39,542 shares during the quarter. Barclays PLC’s holdings in Cardiff Oncology were worth $141,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp bought a new position in Cardiff Oncology in the second quarter worth about $256,000. Rhumbline Advisers purchased a new stake in Cardiff Oncology during the second quarter valued at approximately $102,000. Ground Swell Capital LLC acquired a new stake in Cardiff Oncology in the second quarter valued at approximately $38,000. American Century Companies Inc. boosted its stake in Cardiff Oncology by 98.7% in the second quarter. American Century Companies Inc. now owns 45,360 shares of the company’s stock valued at $101,000 after acquiring an additional 22,536 shares in the last quarter. Finally, Thoroughbred Financial Services LLC purchased a new position in Cardiff Oncology in the second quarter worth $116,000. Institutional investors own 16.29% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. Piper Sandler raised their price objective on Cardiff Oncology from $7.00 to $10.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. HC Wainwright decreased their price target on Cardiff Oncology from $14.00 to $13.00 and set a “buy” rating for the company in a research note on Friday, November 8th.

Insiders Place Their Bets

In other Cardiff Oncology news, Director Gary W. Pace bought 350,115 shares of the firm’s stock in a transaction that occurred on Wednesday, December 11th. The stock was bought at an average cost of $2.60 per share, for a total transaction of $910,299.00. Following the completion of the transaction, the director now directly owns 1,047,876 shares of the company’s stock, valued at approximately $2,724,477.60. This trade represents a 50.18 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 7.80% of the stock is currently owned by insiders.

Cardiff Oncology Trading Down 9.5 %

NASDAQ:CRDF opened at $4.11 on Wednesday. The company has a market capitalization of $210.16 million, a P/E ratio of -4.37 and a beta of 1.76. Cardiff Oncology, Inc. has a 12 month low of $1.44 and a 12 month high of $6.42. The firm has a fifty day simple moving average of $3.43 and a 200-day simple moving average of $2.79.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.